(VCBeat) Apr. 07, 2021 -- EDDA Healthcare and Technology Holding Ltd., an innovator of intelligent surgical robotics and overall precision surgery solution, and its subsidiaries, EDDA Technology (Shanghai) Ltd., EDDA Technology Medical Solutions (Suzhou) Ltd., and EDDA Technology, Inc (Princeton, NJ, USA), (hereafter jointly referred to as "EDDA Technology"),  today announced the closing of a $150 million financing round. The latest round was led by Softbank Vision Fund 2,  with participation from OrbiMed and 3W Fund. Prior investors include Morningside Ventures, Matrix Partners China, SBCVC, BOCGI, Trust Bridge, and Draper Dragon, etc.

EDDA Technology is an innovative leader in the rapidly growing field of medical imaging-assisted precision surgery for cancers. It takes the lead in the domestic and international markets. EEDDA Technology's platform with independent intellectual property rights can provide a series of products and services. With surgical robots as the core, EEDDA Technology provides doctors with overall precision surgery solutions. Its products have been applied in Mayo Clinic, Peking Union Medical College Hospital, Sichuan West China Hospital, Shanghai Ruijin Hospital, and hundreds of other hospitals worldwide.

In creating an IQQA^® platform, EDDA Technology brings Precision 3D medical innovative imaging solutions to support physicians and enable improved workflow and patient care in open/minimally invasive/robotic surgery. The end-to-end enabling platform for surgery provides support for pre-surgical planning and simulation, intra-operative guidance and monitoring, post-operative follow-up evaluation, training.

In 2020, China NMPA granted Category III registration certificate for EEDDA Technology's IQQA^®-Guide as the country's first surgical navigation medical device for soft tissue organs, with a statement describing it as having "significant clinical benefits, increasing interventional accuracy, reducing the number of needle passes and intraoperative CT scanning". The product was also cleared by the US FDA.

The funding will be used for the development of EEDDA Technology's products under R&D, market promotion and commercialization of existing product lines, and promotion of the strategic cooperation planning, so as to build a precision surgery technology platform with intelligent cloud service + surgical robot as the core, enabling doctors to better serve patients.

SoftBank Vision Fund is a subsidiary of Softbank Group that specializes in growth capital and social impact investments. Sectors that the fund invests in include internet-of-things, artificial intelligence (AI), robotics, communications infrastructure, telecoms, computational biology, biotech, cloud technologies and software, consumer internet businesses, financial technology, and mobile apps. 

OrbiMed is a healthcare-dedicated investment firm, with approximately US$5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies.